Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 70

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 70
---
 any of the Investors, constitute the entire agreement between the parties hereto respecting the subject matter of this Agreement and supersedes all prior agreements, negotiations,
understandings, representations and statements respecting the subject matter of this Agreement, whether written or oral. No amendment, modification, alteration, or change in any of the terms of this Agreement shall be valid or binding upon the
parties hereto unless made in writing and duly executed by the Company and the Investors of at least a majority in interest of the Shares then held by the Investors, provided that prior to the Closing the consent of all Investors shall be required.
Notwithstanding the foregoing, (i) this Agreement may not be amended and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver
applies to all Investors in the same fashion and (ii) any amendment to Section 5.5 shall require the consent of each Investor. The Company, on the one hand, and each Investor, on the other hand, may by an instrument signed in writing by
such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively, with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by such Investor or the
Company, respectively.

8.15 . The covenants, representations and warranties made by each party hereto contained in this
Agreement shall survive the Closing and the delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations, warranties, agreements and covenants hereunder.

8.16 . This Agreement is the joint product of each Investor and the Company and each provision of this Agreement
has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

8.17 s. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of
the Securities were determined as a result of arm’s-length negotiations.

[Remainder of Page Intentionally Left Blank.]

24

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written.

| COMPANY:                 |     |                                              |
| TuHURA Biosciences, Inc. |     |                                              |
| By:                      |     |                                              |
|                          |     | Name: James A. Bianco, M.D.                  |